AOD9604

AOD-9604 is a modified peptide fragment derived from human growth hormone (hGH), corresponding to residues 177-191 of the native sequence, with an additional N-terminal tyrosine residue (thus aligning with hGH residues 176-191). This structural modification enhances its stability and receptor binding affinity. The compound is widely studied for its selective lipolytic (fat-burning) properties without the systemic side effects associated with full-length growth hormone.

AOD-9604 exerts its lipolytic effects primarily through activation of the β3-adrenergic receptor (β3-AR) pathway on adipocytes. This activation stimulates adenylate cyclase, increasing intracellular cyclic AMP (cAMP) levels, which in turn promotes lipolysis—the breakdown of stored triglycerides into free fatty acids and glycerol. Unlike full-length hGH, AOD-9604 does not significantly bind to the classical growth hormone receptor, thereby minimizing risks of insulin resistance, hypoglycemia, or cellular proliferation. Some studies suggest the presence of additional complementary pathways contributing to its fat-reducing effects, independent of β3-AR signaling.

• Lipid Metabolism: Investigated as a tool to study targeted fat oxidation and energy expenditure pathways in adipose tissue.
• Obesity Research: Employed in preclinical models to evaluate the potential of peptide-based lipolytic agents.
• Bone and Cartilage Studies: Emerging evidence suggests possible anabolic effects on connective tissue, warranting further investigation.

CAS Number: 221231-10-3
PubChem CID: 71300630
Molecular Formula: C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular Weight: 1,815.1 g/mol (computed by PubChem)
Purity: ≥ 99% (batch-dependent; please refer to the Certificate of Analysis)
Form: Lyophilized powder
Storage: Store at ≤ -20°C in a cool, dry place, protected from light
Solubility: Soluble in sterile water; prepare working solutions per laboratory protocol. (Note: Slight solubility variations may exist in other solvents; follow standard laboratory guidelines.)